Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Sexual Health
Master upstream regulator of the reproductive axis — the GnRH releaser.
Peptide B
Sexual Health
FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder.
Typical vial
5 mg
Typical dose
50-200 mcg
Half-life
~3-4 minutes (plasma)
FDA status
Not FDA approved as a therapeutic.
Typical vial
10 mg
Typical dose
1000-2000 mcg
Half-life
~2.7 hours
FDA status
FDA approved. Bremelanotide (Vyleesi) was approved in June 2…
Kisspeptin-10 effects
PT-141 (Bremelanotide) effects
Kisspeptin-10 side effects
PT-141 (Bremelanotide) side effects
Kisspeptin-10 dosing ranges
Libido / HPG axis stimulation
50-200 mcg · Once or twice daily (SubQ) · Cycle-based, 2-4 weeks per cycle
IVF trigger (clinical, IV)
6.4-12.8 nmol/kg · Single dose 36 hours pre-collection · One-time
PT-141 (Bremelanotide) dosing ranges
HSDD treatment (FDA-approved dose)
1750 mcg · As needed, at least 45 minutes before activity · As needed, max 8 doses per month
General sexual function enhancement
1000-2000 mcg · As needed, 45-60 minutes before activity · As needed
Kisspeptin-10: Master upstream regulator of the reproductive axis — the GnRH releaser. Typical dose 50-200 mcg. PT-141 (Bremelanotide): FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder. Typical dose 1000-2000 mcg. Both fall under the Sexual Health category.
Stacking Kisspeptin-10 with PT-141 (Bremelanotide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
Kisspeptin-10 is typically dosed: Once or twice daily (SubQ) for Libido / HPG axis stimulation; Single dose 36 hours pre-collection for IVF trigger (clinical, IV). PT-141 (Bremelanotide) is typically dosed: As needed, at least 45 minutes before activity for HSDD treatment (FDA-approved dose); As needed, 45-60 minutes before activity for General sexual function enhancement.
Kisspeptin-10: Not FDA approved as a therapeutic. PT-141 (Bremelanotide): FDA approved. Bremelanotide (Vyleesi) was approved in June 2019 for treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free